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Abstract
Background and Aims: Hepatitis C Virus (HCV)-related liver disease progresses more rapidly in individuals co-infected with
Human Immunodeficiency Virus-1 (HIV), although the underlying immunologic mechanisms are unknown. We examined
whether HIV-specific T-cells are identified in the liver of HCV/HIV co-infected individuals and promote liver inflammation
through bystander immune responses.
Methods: Ex-vivo intra-hepatic lymphocytes from HCV mono-infected and HCV/HIV co-infected individuals were assessed
for immune responses to HIV and HCV antigens by polychromatic flow cytometry.
Results: HCV/HIV liver biopsies had similar frequencies of lymphocytes but lower percentages of CD4
+ T-cells compared to
HCV biopsies. In co-infection, intra-hepatic HIV-specific CD8
+ and CD4
+ T-cells producing IFN-c and TNF-a were detected
and were comparable in frequency to those that were HCV-specific. In co-infected individuals, viral-specific CD8
+ T-cells
produced more of the fibrogenic cytokine, TNF-a. In both mono- and co-infected individuals, intra-hepatic HCV-specific T-
cells were poorly functional compared to HIV-specific T-cells. In co-infection, HAART was not associated with a
reconstitution of intra-hepatic CD4
+ T-cells and was associated with reduction in both HIV and HCV-specific intra-hepatic
cytokine responses.
Conclusion: The accumulation of functional HIV-specific T-cells in the liver during HCV/HIV co-infection may represent a
bystander role for HIV in inducing faster progression of liver disease.
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Introduction
Approximately 25% of Human Immunodeficiency Virus-1 (HIV)
infected individuals are also infected with Hepatitis C Virus (HCV)
[1]. HIV adversely affects each stage of the natural history of HCV
infection. Fewer individuals recover spontaneously from HCV
i n f e c t i o nw h e na l s oi n f e c t e dw i t hH I V[ 2 ] .A m o n gt h o s ew i t h
persistent HCV infection, HIV co-infection is associated with higher
HCV viremia and more rapid progression to cirrhosis and
hepatocellular carcinoma [3]. A recent meta-analysis showed that
HIV co-infection increased the risk of histological hepatic cirrhosisby
two-fold and clinically decompensated liver disease by six-fold [4]. In
addition, HCV co-infection is associated with increased incidence of
HAART (highly active antiretroviral therapy) related liver injury [5].
The mechanisms for hepatic damage in HCV/HIV co-infection
are poorly defined. Although intra-hepatic T-cell immune
responses are necessary for HCV clearance, they have also been
shown to play a central role in mediating hepatocellular injury by
direct cytotoxicity or indirectly by releasing cytokines. In this
regard, IFN-c has been shown to be anti-fibrogenic, whereas,
TNF-a activates hepatic stellate cells, which induce fibrosis, and
likely contributes to progression to cirrhosis [6,7].
Potent and broad CD4
+ and CD8
+ T-cell immunity are
important for virologic control in both HCV and HIV viral
infections. Ex-vivo HCV-specific CD8
+ T-cell responses in
peripheral blood mono-nuclear cells (PBMCs) from mono-infected
individuals are generally weak [8]. Although, peripheral HCV-
specific CD4
+ and CD8
+ T-cell responses are somewhat weaker in
HCV/HIV co-infected individuals [9], similar frequencies of
intra-hepatic HCV-specific responses appear to be obtained in
HCV versus HCV/HIV co-infection [10,11]. However, ex-vivo
HIV-specific CD8
+ T-cell responses in PBMCs from HIV mono-
infected individuals are about one log higher than ex-vivo HCV-
specific responses in HCV mono-infection. In addition, impair-
ment in cellular immune responses to HCV compared to HIV has
been shown in HCV/HIV co-infection [12]. HIV-specific CD8
+
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individuals [13]. Such high frequencies of HIV-specific T-cells
circulating in peripheral blood led us to question whether these
cells could also migrate to the liver in HCV/HIV co-infection and
through bystander responses add to the inflammation induced by
HCV-specific T-cells.
Materials and Methods
Study participants
HCV mono-infected and HCV/HIV co-infected individuals
who required liver biopsies for work up of liver disease were
recruited for the study (see Results and Table 1). All study
participants provided informed, written consent and the study
protocol was approved by the research ethics board at the
University of Toronto and St. Michael’s Hospital. Both blood and
liver biopsy samples were received from each participant.
Isolation of intra-hepatic lymphocytes from liver biopsy
Liver biopsy samples were washed in RPMI-1640 to remove
contaminating blood lymphocytes, manually homogenized with a
plastic plunger, and treated with DNase (0.002%, Sigma) and
collagenase IV (0.02%, Sigma) for 30 minutes, stirring at 37uC.
The digested cell suspension was filtered through a 70 mm strainer,
washed and re-suspended in R-10 medium (10% fetal calf serum).
IFN-c ELISPOT epitope mapping in PBMCs
In order to identify candidate epitope-specific responses to be
detected in ex-vivo liver samples, we first mapped antigen-specific
T-cell responses in blood against the entire HIV-1 clade-B and
HCV-1a proteome using the matrix approach by IFN-c ELI-
SPOT assay as described previously [14]. Mapped peptides were
then pooled to evaluate hepatic responses. In order to address the
possibility that differing epitopes were only targeted in the liver, we
also used four peptide pools that previously were shown to target a
majority of responses. These pools spanned HIV-Gag and HCV-
NS3, HCV-NS4 and HCV-Core protein (2 mg/peptide/ml, from
National Institute of Health Reagent Program). Of the HCV
pools, the pool that gave the strongest ELISPOT response in
PBMCs was used for hepatic cell stimulation (see below).
Ex-vivo stimulation and intracellular staining
All the extracted cells from each liver biopsy were split in three
wells and stimulated on the same day as PBMCs. 1610
6 PBMCs
and liver- isolated cells were stimulated with either DMSO, HIV
or HCV peptide pools as described previously[14]. HIV pools
consisted of peptides that were screened by the matrix approach in
that individual plus the HIV-Gag pool. Likewise, HCV pools
consisted of mapped peptides plus an HCV pool that gave the
strongest response in PBMCs. CD107a antibody (PE-Cy5, BD
Pharmingen) was added at the time of stimulation. The following
antibodies were used for staining: CD8-PE Texas-Red (Beckman
Coulter), CD4-Pacific Blue (e-Bioscience), CD3- APCCY7, IFNc-
FITC, TNFa-PECY7, IL2-APC, MIP-1b-PE (BD Bioscience),
PD-1 FITC (Biolegend) and dead cell stain Aqua (Invitrogen,
Molecular Probes).
Flow cytometry
Cells were analyzed on a multi-color FACSAria flow cytometer
(BD Biosciences). For Blood samples between 500,000 to
1,000,000 total events and for liver biopsy samples between
50,000 to 200,000 total events were collected. Data analysis was
performed using FlowJo version 8.6 (Treestar Inc., San Carlos,
CA). Polychromatic FlowJo data were analyzed with PESTLE
software, and pie-chart graphs were generated using SPICE
software (obtained from M. Roederer, National Institutes of
Health, Bethesda MD).
Tetramer Staining
Multi-parameter analysis of HIV-Gag: 77–85 (SLYNTVATL:
SL9) specific CD8
+ T-cells was conducted in both blood and liver
of co-infected individuals initially identified with a positive
ELISPOT response to the 15-mer HIV peptide including SL9
epitope, using the corresponding tetramer (iTAg MHC Class-I
tetramer, Beckman Coulter). Tetramer staining was performed
prior to peptide stimulation, at room temperature for 20 minutes.
Tetramer stained cells were then washed and stimulated with
10 mg/ml of SL9 peptide followed by ICS staining as mentioned
above. Additional HIV, HCV and CMV-specific pentamer
staining (Pro5 MHC class I Pentamers -Proimmune) was
conducted followed by PD-1 staining.
Table 1. Characteristics of HCV mono-infected and HCV/HIV co-infected individuals, untreated for HCV.
HCV mono-infected (n=6) HCV/HIV-1 Co-infected p value
not on HAART (n=8) on HAART (n=12)
Age (y, mean) 51(63.5) 42(65.7) 41(62.8)
Sex (no. male) 5 8 11
HCV genotype (no. type 1) 5 7 11
HCV plasma VL (log10 IU/ml, mean) 5.036(0.51)*
a 6.22(60.12)* 6.3(60.08)
aa *p,.05
HIV plasma VL (log10 copies/ml, mean) na 6.5(60.15) 1.43(60.37) p,.01
CD4 count/ml (mean) na 492(634.4) 599(656.9) p..05
ALT (mean) 65(613)* 70(616) 109(652)* *p,.05
Liver Biopsy Inflammation Grade (mean) 1.7(60.16) 1.9(60.25) 1.7(60.15) p..05
Liver Biopsy Fibrosis Score (mean) 3(60.6)* 1.5(60.3)* 2(60.5) *p,.05
Lymphocytes count/liver biopsy1 (mean) 43884(611007) 47095(67410) 59414(65165) p..05
1. Normalized to 100,000 events count.
na=not applicabale.
no=number of participants.
HAART individuals were treated.1 year.
doi:10.1371/journal.pone.0003454.t001
HCV/HIV Co-Infection
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Data were analyzed by performing two-tailed non-parametric
Mann-Whitney test using GraphPad Prism version 4.00. P-
values#0.05 were considered significant.
Results
Subject Characteristics
Three groups of individuals were studied as depicted in Table 1;
HCV mono-infected (n=6), HCV/HIV co-infected who were not
receiving HAART (n=8) and HCV/HIV co-infected who were
receiving HAART for greater than one year at the time of
evaluation (n=12). All individuals never received prior treatment
for HCV and underwent liver biopsies for staging and evaluation
for pegylated-interferon/ribavirin treatment. HCV/HIV co-in-
fected individuals had higher HCV viral loads. On average, CD4
T-cell counts of HIV infected individuals were .400/ml in both
groups. Of note, the mean hepatic fibrosis scores were higher in
the HAART treated and mono-infected groups in this cohort,
indicating that individuals in these groups had more advanced
disease at the time of biopsy in this study.
Characterizing intra-hepatic lymphocytes
Although similar frequencies of intra-hepatic lymphocytes were
obtained in dual versus mono-infection, HAART-treated individuals
showed a trend towards greater percentages of lymphocytes in their
biopsies (Figure 1a). The percentage of intra-hepatic CD4
+ T-cells
was significantly reduced in dual infection [31.6%613.8 for HCV vs
6.5%62.9, for HCV/HIV therapy naı ¨ve, p,0.01], and was not
associated with any improvement in HAART-treated individuals, as
previously shown in the gut[15] (Figure 1b). However, compared to
HCV mono-infected individuals the percentage of intra-hepatic
CD8
+ T-cells was higher in both co-infected groups [33.8%65.5%
for HCV vs 67.3%615.5% for HCV/HIV therapy naı ¨ve vs
59.5615.1% for HCV/HIV on HAART, p,0.01] (Figure 1b).
Intra-hepatic viral specific immune responses
To determine the presence of intra-hepatic viral specific T-cell
responses, liver isolated cells were stimulated with HCV and HIV
peptide pools. Summary data of viral specific responses are depicted
in Figure 2. In response to stimulation with HIV peptide pool,
untreated co-infected individuals showed significantly higher
frequencies of intra-hepatic CD4
+ T-cells producing IFN-c,
compared to HCV mono-infected [0.1660.05% vs 0.0260.01%,
p,0.05], and HAART-treated co-infected individuals
[0.1660.05% vs 0.0360.05%, p,0.05] (Figure 2a). Untreated
co-infected individuals showed a trend towards lower frequencies of
intra-hepatic IFN-c producing CD4
+ T-cells in response to HCV
peptides. Surprisingly, HAART-treated co-infected individuals had
significantly reduced HCV-specific IFN-c producing CD4
+ T-cells
when compared to untreated co-infected individuals [0.0260.01%
vs 0.4660.11%, respectively, p,0.01] (figure 2a).
Therapy naı ¨ve co-infected subjects had greater IFN-c produc-
ing CD8
+ T-cells in response to HIV peptides compared to HCV
mono-infected individuals [1.3960.37% vs 0.0260.0%, p,0.05],
and HAART was associated with a significant reduction in the
frequencies of these cells [1.3960.37% vs 0.3060.26%, p,0.05]
(figure 2b). Although there was a trend for enhanced intra-hepatic
CD8
+ T-cells producing IFN-c in response to HCV peptides in
therapy-naive co-infection compared to HCV mono-infection, this
was not found to be statistically significant. HAART on the other
hand, was associated with a significant reduction in HCV-specific,
intra-hepatic CD8
+ T-cells producing IFN-c [1.360.37% vs
0.0360.01%, p,0.05] (figure 2b).
Similarly, co-infected individuals had significantly greater intra-
hepatic TNF-a expressing CD4
+ T-cells after HIV peptide
stimulation compared to HCV mono-infected [0.260.05 vs
0.0260.01, p,0.01], although HAART had no significant effect
on their frequencies (Figure 2c). HCV mono-infected individuals
showed significantly higher frequencies of HCV-specific TNF-a
producing CD4
+ T-cells compared to HAART-treated co-infected
individuals [0.9160.25% for HCV vs 0.2360.20 for HCV/HIV
on HAART, p,0.01] (figure 2c), but did not show significant
differences with the untreated co-infected group.
The therapy-naı ¨ve co-infected group showed significantly
higher frequencies of intra-hepatic TNF-a producing CD8
+ T-
cells in response to both HIV-1 and HCV antigens. Both types of
Figure 1. Characteristics of intra-hepatic lymphocytes from
HCV and HCV/HIV co-infected individuals. Frequencies of
lymphocytes obtained from liver biopsies normalized to total live
mononuclear cell count from FACS analysis are illustrated in (a) with
percent composition of intra-hepatic CD4 and CD8 expressing T-cells
shown in (b).
doi:10.1371/journal.pone.0003454.g001
HCV/HIV Co-Infection
PLoS ONE | www.plosone.org 3 October 2008 | Volume 3 | Issue 10 | e3454responses were shown to be reduced in the HAART group [HIV-
specific: 0.0260.01% vs 1.0860.21% vs 0.1160.06%; HCV vs
HCV/HIV vs HCV/HIV on HAART, p,0.01 for all], [HCV-
specific: 0.5960.2% vs 1.1660.19% vs 0.2060.07%; HCV vs
HCV/HIV vs HCV/HIV on HAART, p,0.05 for all] (figure 2d).
Multi-parameter analysis of T-cell functions
To study the functional profile of virus-specific T-cells in HCV/
HIV co-infection, simultaneous expression of 5 distinct CD8
+ T-
cell markers were analyzed in 3 individuals within each cohort
using a previously developed multicolor flow cytometry meth-
od[16]. Expression levels of degranulation marker CD107a and
cytokines IFN-c, TNF-a and IL-2, as well as the chemokine MIP-
1b were simultaneously measured in response to HCV or HIV
peptides in both blood and liver of each individual. Figure 3
depicts a representative multi-parameter analysis of CD8
+ T-cell
responses in liver and blood of a therapy-naı ¨ve, co-infected subject
in response to HIV and HCV peptide pools. These data indicate
Figure 2. Antigen-specific cytokine production by intra-hepatic T-cells in HCV mono-infection and HCV/HIV co-infection. Figure (a)
represents the summary data of the percentage of intra-hepatic CD4
+ T-cells expressing IFN-c in response to either HCV or HIV peptide stimulation in
all the three studied cohorts, with figure (b) representing the same responses by CD8
+ T-cells. Figures (c) and (d) represent the percentage of viral-
specific, intra-hepatic TNF-a producing CD4
+ and CD8
+ T-cells respectively.
doi:10.1371/journal.pone.0003454.g002
HCV/HIV Co-Infection
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+ T-cells expressing one or
more functions are detectable in the liver and blood. Compared to
blood, the frequency of HIV-specific T-cells producing CD107a
and IL-2 was shown to be significantly higher in the liver of
therapy-naı ¨ve, co-infected individuals. Consistent with previously
reported data[10], HCV-specific responses were compartmental-
ized to the liver and stronger than peripheral HCV-specific
responses (Figure 3c).
Recognition of functional CTL, specific for the HLA-
A0201-restricted HIV-SL9 epitope in HCV/HIV co-infected
liver
To determine if T-cells specific for an HIV immuno-dominant
epitope are present in HCV/HIV co-infected liver, we quantified
CD8
+ T-cells specific for HLA-A*0201-restricted SLYNTVATL
(SL9) epitope in the liver of individuals with positive SL9 responses
in their blood. We identified 3 co-infected HLA-A*0201
individuals, among them one showed a response to the SL9
epitope of HIV-Gag antigen. Figure 4 shows the multi-parameter
analysis of tetramer positive CD8
+ T-cells in blood and liver of this
therapy-naı ¨ve, co-infected individual. The tetramer cytokine
response pattern was shown to be different in the liver compared
to blood of the same individual, with diminished intra-hepatic
tetramer-specific IFN-c responses and an increase in both CD107a
and TNF-a responses, with the majority of SL9 tetramer positive
cells expressing these two markers.
We also included CMV as a non-hepatotropic control virus in
our liver analysis. Using a pool of HLA-A*0201- and HLA-
A*2402-restricted, CMV-specific pentamers, we did not detect any
CMV-specific CD8
+ T-cells in HCV/HIV co-infected liver,
although we could readily detect them in blood (Figure 4c).
Hierarchy of viral-specific CD8
+ T-cell function during
HCV mono and HCV/HIV co-infection
Using the panel of markers TNF-a, IFN-c, MIP-1b, IL-2, and
CD107a, we characterized the ability of CD8
+ T-cells to
simultaneously exert these ‘functions’ in response to both HCV
and HIV peptides. Figure 5 depicts a representative functional
profile of virus specific CD8
+ T-cells in blood and liver during
HCV/HIV co-infection (Fig. 5a) and HCV mono-infection
(Fig. 5b). Analysis of co-infected subjects demonstrates a very
limited functional hierarchy of HCV-specific T cells in the blood,
with majority of T-cells producing one function. HIV-specific T-
cells from blood had a more expanded functional hierarchy. In
accordance with previous reports on HIV mono-infected individ-
uals [16], cells expressing all 5 functions were absent in the blood
of co-infected subjects, mainly due to lack of IL-2 production. In
co-infection, intra-hepatic CD8
+ T-cells responding to HCV
peptides were within the single-responding and 2+ populations.
Intra-hepatic CD8
+ T-cell responses to HIV peptides produced a
larger spectrum of responses. CD107a responding cells were
represented in nearly all of the different HIV-specific populations
in the liver of co-infected individuals.
As expected, HCV-specific responses in the blood of HCV
mono-infected subjects were mainly single functional. The profile
of HCV-specific responses in the liver of HCV mono-infected
individuals showed the appearance of a very small population of
4+ responding cells in the liver.
We and others have considered a cutoff point of more than 2
simultaneously expressed markers to demonstrate poly-functional
characteristic of responding T-cells [16,17]. Figure 5c shows a
comparison between average frequency of intra-hepatic viral-
specific responses within the pool of CD8
+ T-cell populations
expressing 2 markers or less, and those within the pool of
populations expressing more than 2 markers simultaneously. For
both HCV and HIV-specific CD8
+ T-cells the majority of
responses had two or less functions. However, intra-hepatic
HIV-specific responses demonstrated more poly-functionality,
compared to HCV-specific responses either within co-infected or
mono-infected individuals [0.0560.01 vs 0.00760.00, p,0.05;
HIV-specific responses vs HCV-specific responses in HCV/HIV
co-infected group]; [0.0560.01 vs 0.0160.00, p,0.05; HIV-
specific responses in HCV/HIV co-infected group vs HCV-
specific responses in HCV mono-infected group]. In summary,
although viral-specific T-cells, simultaneously expressing all 5
measured markers were rarely found in the liver, intra-hepatic
HIV-specific T-cells showed greater functional capacity when
compared to those being HCV-specific.
Based on the recently highlighted role of PD-1 contributing to
the dysfunction of T-cells in chronic viral infections, we also
determined whether HIV and HCV-specific intra-hepatic T-cells
differ in the degree of PD-1 expression. In an HCV/HIV co-
infected liver, we found that 100% of intra-hepatic HCV-specific
CD8
+ T-cells were PD-1 positive, compared to 48.8% of those
cells that were HIV-specific (Figure 5d).
Discussion
This is the first study to demonstrate the presence of HIV-
specific T-cells within the liver of HCV/HIV co-infected
individuals. The finding of HIV-specific T-cells within liver of
co-infected individuals may not altogether be surprising, given the
high frequencies of HIV-specific CD8
+ T-cells found in the
peripheral blood in untreated HIV infection. Nevertheless, it is
surprising to find functional T-cells of such viral specificities to be
accumulating in liver. In contrast, we could not detect CMV-
specific T-cells in co-infected liver despite their abundance in
blood indicating that different viruses target T-cells to the liver.
Recent studies have demonstrated that systemic viral infections
may recruit viral-specific T-cells to the liver. The significance of
non-hepatotropic viral-specific T-cells that are found in liver is
unclear. It has been postulated that the liver can non-selectively
trap activated T-cells during any infection, and thus act as a ‘sink’
or ‘graveyard’[18], however it is unclear whether these cells are
rendered anergic while traveling in the liver or contribute to
inflammation and damage as a result of bystander activation. Of
note, is that hepatitis has been observed in measles [19], SARS
[20] and in 20% of individuals with acute HIV infection [21].
Polakos et. al.[22] found that some individuals infected with
influenza-A develop transaminitis and showed in a murine
influenza model that influenza-specific CD8
+ T-cells migrate to
Figure 3. Polychromatic FACS analysis of viral-specific T cells in HCV/HIV co-infection. Shown are representative FACS data of the HIV and
HCV specific multi-parameter CD8
+ T-cell responses from (a) liver and (b) blood of subject OM 405, a therapy-naı ¨ve HCV/HIV co-infected individual,
after in vitro stimulation using pool of HIV and HCV peptides. Initial gating on forward scatter area (FSC-A) versus height (FSC-H) was used to remove
doublets. The events were further gated on forward scatter (FSC) versus the dead cell marker to remove dead cells. Lymphocytes were gated on the
remaining live cells on a FSC versus SSC plot. Gates on CD3
+/CD8
+ cells were then generated. All responses are gated on a CD3
+/CD8
+ population and
presented against TNF-a on the x-axis. Figure (c) shows a comparison of the frequency of HIV and HCV-specific CD8
+ T-cells in the liver and blood of
therapy-naı ¨ve, co-infected individuals. All intra-hepatic HCV-specific responses are significantly stronger than peripheral HCV-specific responses.
doi:10.1371/journal.pone.0003454.g003
HCV/HIV Co-Infection
PLoS ONE | www.plosone.org 6 October 2008 | Volume 3 | Issue 10 | e3454Figure 4. Tetramer positive cells specific for HIV are identified in the liver in HCV/HIV co-infection. Representative multi-parameter
FACS plots of HIV-SLYNTVATL (SL9) tetramer positive/ CD8
+ T-cells are shown in a) blood and b) liver of a co-infected individual (OM 403). Gating
scheme on tetramer positive responses are based on initial gating on responses from the tetramer negative population. Figure (c) represents the
HCV/HIV Co-Infection
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Non-hepatotropic viruses such as HIV, CMV and EBV, in general
do not induce chronic hepatitis, thus, it is possible that the co-
existence of hepatotropic viruses may alter the hepatic environ-
ment to allow recruitment of activated T-cells non-specifically.
This could be due to an up-regulation of integrins such as ICAM-1
and VCAM-1 in hepatic sinusoids as previously shown during
HCV infection [23] that could enhance T-cell recruitment. In this
regard, Spangenberg et. al.[24] demonstrated the presence of
influenza-specific T-cells in about 50% of liver biopsies from HCV
mono-infected individuals.
There are several lines of evidence demonstrating that the liver
efficiently clears many foreign pathogens, including RNA viruses.
It is shown that liver is a major organ for clearing Simian
Immunodeficiency Virus in rhesus monkeys [25]. There is also
evidence for the detection of HIV RNA in the liver of HIV
infected individuals [26]. These findings support the identification
of HIV-specific T-cells in the liver. In HCV/HIV co-infection, it is
possible that intra-hepatic HCV-specific CD4
+ T-cells become
infected with HIV and recruit HIV-specific immune responses to
this site. Evidence for these potential mechanisms will need further
analysis on liver biopsies of co-infected individuals.
Our analysis of liver biopsies from HCV/HIV co-infected
individuals not only demonstrate that HIV-specific T-cells
producing IFN-c and TNF-a are detected in the liver, but also
exhibit comparable frequencies of responses to those that are
HCV-specific. This observation may explain the added contribu-
tion of HIV-specific immune responses to the ongoing intra-
hepatic damage induced by HCV-specific T-cell responses that are
inefficient in clearing the virus. Therapy naı ¨ve co-infected
individuals demonstrated a higher frequency of intra-hepatic
CD8
+ T-cells that produce TNF-a in response to both HCV and
HIV antigen stimulation compared to HCV mono-infected
individuals. In addition, we identified CD8
+ T-cells specific for
an immunodominant HIV epitope in co-infected liver, demon-
strating high frequency of TNF-a expression. Intra-hepatic TNF-a
has been previously associated with liver fibrosis, and the
accumulation of cells expressing this marker may explain in part
the faster rate of liver disease progression found in HCV/HIV co-
infection. Further comparisons of TNF-a responses between
immunodominant HCV and other HIV epitopes in a larger
cohort of individuals are warranted. Contrary to our expectation,
viral-specific, intra-hepatic levels of IFN-c were also higher in the
therapy-naı ¨ve co-infected group, which would be against the
expected protective role of IFN-c. However, we interpret this
observation as a potential effect of the fibrogenic TNF-a to mask
IFN-c protection. On the other hand, viral-specific T-cells are
composed of several major populations with unique functional
patterns. Therefore, measurement of only one or two T-cell
functions may not provide a comprehensive picture of the quality
of T-cell responses.
Recent lines of evidence demonstrate the importance of the
qualitative rather than quantitative characteristics of CD8
+ T-cell
responses to efficient viral control [13,27]. The significance of T-
cell populations simultaneously representing 5 different functions
has been discussed as a hierarchical functional model in viral
infections such as CMV and EBV which are effectively controlled
by respective CD8
+ T-cells [16]. HCV-specific CD8
+ T-cells were
not poly-functional which is consistent with the notion that
although HCV-specific T-cells are found in hepatic tissue, their
loss of poly-functionality may be associated with inefficient control
of HCV replication. HIV-specific T-cells in the liver of co-infected
individuals however, simultaneously could express 4 and 5 of the
measured markers. Recently, T-cell exhaustion has been related to
signaling pathways through PD-1 [28,29]. Our analysis of PD-1
levels of antigen-specific CD8
+ T-cells from co-infected liver
demonstrates higher expression of PD-1 on HCV-specific T-cells,
compared to those specific for HIV, supporting the notion that the
former are less functional. The observed poly-functionality of
intra-hepatic HIV-specific T-cells, should have little effect on
HCV replication but would further enhance the cytokine milieu
induced from bystander activation, and contribute to liver damage
during co-infection with HCV. In this regard, we found that the
degranulation marker CD107a dominates the HIV-specific CD8
+
T-cell responses in the liver, with the majority of the responding
cells expressing CD107a, a surrogate marker for the cytotoxic
function of CD8
+ T-cells. Activated HIV-specific CD8
+ T-cells
with the potential to degranulate could induce bystander damage.
In addition, the release of chemokines such as MIP-1b by the same
cells could also attract further lymphocytes without HCV
specificity to the liver. Bystander function of these non-specific
T-cells could expand the tissue damage triggered by HCV
infection and ultimately activate fibrogenesis.
We found that the frequency of CD4
+ T-cells within livers of co-
infected individuals was reduced compared to HCV mono-
infection. Surprisingly, HAART did not appear to reconstitute
the CD4
+ T-cell population within liver. Despite this defect of
CD4
+ T-cell help, comparable frequencies of HCV-specific-CD8
+
T-cells were found in co-infected livers. HAART-treated biopsies
showed further reduced frequencies of HCV-specific responses.
These data support previous findings that show HAART induces
CD4
+ T-cell recovery but not any restoration of HCV-specific T-
cell responses peripherally [30]. Further investigation is needed to
clarify the role of CD4
+ T-cell help in affecting the frequencies of
HCV-specific CD8
+ T-cells in HCV/HIV-1 co-infection.
HAART was also associated with a reduction in frequencies of
HIV-specific T-cell responses within liver, indicating that
removing the HIV antigenic load may also reduce the opportunity
for such cells to accumulate within hepatic tissue.
Here, we propose a novel mechanism for enhanced HCV-
related liver disease progression in HIV co-infection; that of
bystander activation and induced inflammation from HIV-specific
T-cells accumulated in the liver. Our data however are limited in
the cross-sectional nature of our cohort, the low number of
analyzed liver biopsies and the narrow range of CD4
+ T-cell
counts among the studied individuals. We should also acknowl-
edge that ex-vivo functional T-cell capacity may not exactly reflect
the situation in-vivo. Further studies, particularly, those which are
prospective are warranted in order to understand the role that
HIV-specific T-cells play in contributing to fibrosis and in
particular how HAART modulates these responses.
frequency of CD8
+ T-cells specific for HCV, HIV and CMV in HCV/HIV co-infected liver (OM 385). Liver isolated mononuclear cells were stained with
pools of HLA-A*0201 and HLA-A*2402-restricted pentamers (Pro5 MHC class I Pentamers, Proimmune), followed by staining for cell surface markers
CD3 and CD8. The following pentamers were used for each group: HCV pentamers: NS3-CINGVCWTV and NS3-KLVALGINAV; HIV pentamers: Pol-
ILKEPVHGV and Gag p24-TLNAWVKVV; CMV Pentamers: pp65-NLVPMVATV and pp65-QYDPVAALF. No CD8
+ T-cells specific for CMV were detected in
this co-infected liver sample. Similar findings were found in another individual (data not shown).
doi:10.1371/journal.pone.0003454.g004
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PLoS ONE | www.plosone.org 8 October 2008 | Volume 3 | Issue 10 | e3454Figure 5. Characterization of the functional hierarchy of viral specific CD8
+ T-cells in HCV/HIV co-infection. Representative functional
profiles of virus specific CD8
+ T-cells in blood and liver are depicted from an individual with (a) HCV/HIV co-infection (OM 405) and from an individual
with (b) HCV mono-infection (OM 428). For multi-parameter analysis, the Boolean gating platform was used to create all of the possible combinations
of functions, generating 32 response patterns for 5 of the different functions analyzed. All data are reported after background correction. Nonspecific
HCV/HIV Co-Infection
PLoS ONE | www.plosone.org 9 October 2008 | Volume 3 | Issue 10 | e3454Acknowledgments
We are grateful to the patients who contributed their time and effort to this
study. We would also like to thank Ms. Dionne White for her expertise and
assistance in flow cytometry and Dr. George Makedonas for SPICE and
PESTLE software training. We specially thank Dr. Mario Roederer for
providing us with the mentioned software.
Author Contributions
Conceived and designed the experiments: BV RBJ RK MB DW MAO.
Performed the experiments: BV FYY. Analyzed the data: BV RBJ Ps RK
MB DW MAO. Contributed reagents/materials/analysis tools: DW CK
ML AC RH MAO. Wrote the paper: BV MAO.
References
1. Thomas DL, Shih JW, Alter HJ, Vlahov D, Cohn S, et al. (1996) Effect of
human immunodeficiency virus on hepatitis C virus infection among injecting
drug users. J Infect Dis 174: 690–695.
2. Kim AY, Schulze zur Wiesch J, Kuntzen T, Timm J, Kaufmann DE, et al.
(2006) Impaired hepatitis C virus-specific T cell responses and recurrent hepatitis
C virus in HIV coinfection. PLoS Med 3: e492.
3. Pol S, Lamorthe B, Thi NT, Thiers V, Carnot F, et al. (1998) Retrospective
analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in
a large cohort of drug users. J Hepatol 28: 945–950.
4. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, et al. (2001) Influence of
human immunodeficiency virus infection on the course of hepatitis C virus
infection: a meta-analysis. Clin Infect Dis 33: 562–569.
5. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD (2000) Hepatotoxicity
associated with antiretroviral therapy in adults infected with human immuno-
deficiency virus and the role of hepatitis C or B virus infection. Jama 283: 74–80.
6. Kitamura K, Nakamoto Y, Akiyama M, Fujii C, Kondo T, et al. (2002)
Pathogenic roles of tumor necrosis factor receptor p55-mediated signals in
dimethylnitrosamine-induced murine liver fibrosis. Lab Invest 82: 571–583.
7. Simeonova PP, Gallucci RM, Hulderman T, Wilson R, Kommineni C, et al.
(2001) The role of tumor necrosis factor-alpha in liver toxicity, inflammation,
and fibrosis induced by carbon tetrachloride. Toxicol Appl Pharmacol 177:
112–120.
8. Wedemeyer H, He XS, Nascimbeni M, Davis AR, Greenberg HB, et al. (2002)
Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic
hepatitis C virus infection. J Immunol 169: 3447–3458.
9. Valdez H, Carlson NL, Post AB, Asaad R, Heeger PS, et al. (2002) HIV long-
term non-progressors maintain brisk CD8 T cell responses to other viral
antigens. Aids 16: 1113–1118.
10. Alatrakchi N, Graham CS, He Q, Sherman KE, Koziel MJ (2005) CD8+ cell
responses to hepatitis C virus (HCV) in the liver of persons with HCV-HIV
coinfection versus HCV monoinfection. J Infect Dis 191: 702–709.
11. Graham CS, Curry M, He Q, Afdhal N, Nunes D, et al. (2004) Comparison of
HCV-specific intrahepatic CD4+ T cells in HIV/HCV versus HCV.
Hepatology 40: 125–132.
12. Lauer GM, Nguyen TN, Day CL, Robbins GK, Flynn T, et al. (2002) Human
immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual
comparison of cellular immune responses against two persistent viruses. J Virol
76: 2817–2826.
13. Betts MR, Ambrozak DR, Douek DC, Bonhoeffer S, Brenchley JM, et al. (2001)
Analysis of total human immunodeficiency virus (HIV)-specific CD4(+)a n d
CD8(+) T-cell responses: relationship to viral load in untreated HIV infection.
J Virol 75: 11983–11991.
14. Sheth PM, Danesh A, Shahabi K, Rebbapragada A, Kovacs C, et al. (2005)
HIV-specific CD8+ lymphocytes in semen are not associated with reduced HIV
shedding. J Immunol 175: 4789–4796.
15. Guadalupe M, Reay E, Sankaran S, Prindiville T, Flamm J, et al. (2003) Severe
CD4+ T-cell depletion in gut lymphoid tissue during primary human
immunodeficiency virus type 1 infection and substantial delay in restoration
following highly active antiretroviral therapy. J Virol 77: 11708–11717.
16. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, et al. (2006) HIV
nonprogressors preferentially maintain highly functional HIV-specific CD8+ T
cells. Blood 107: 4781–4789.
17. Makedonas G, Betts M (2006) Polyfunctional analysis of human t cell responses:
importance in vaccine immunogenicity and natural infection. Springer Sem
Immunol 28: 209–219.
18. Crispe IN, Dao T, Klugewitz K, Mehal WZ, Metz DP (2000) The liver as a site
of T-cell apoptosis: graveyard, or killing field? Immunol Rev 174: 47–62.
19. Khatib R, Siddique M, Abbass M (1993) Measles associated hepatobiliary
disease: an overview. Infection 21: 112–114.
20. Chan HL, Kwan AC, To KF, Lai ST, Chan PK, et al. (2005) Clinical
significance of hepatic derangement in severe acute respiratory syndrome.
World J Gastroenterol 11: 2148–2153.
21. Kahn JO, Walker BD (1998) Acute human immunodeficiency virus type 1
infection. N Engl J Med 339: 33–39.
22. Polakos NK, Cornejo JC, Murray DA, Wright KO, Treanor JJ, et al. (2006)
Kupffer cell-dependent hepatitis occurs during influenza infection. Am J Pathol
168: 1169–1178; quiz 1404–1165.
23. Banner BF, Allan C, Savas L, Baker S, Barnard G, et al. (1997) Inflammatory
markers in chronic hepatitis C. Virchows Arch 431: 181–187.
24. Spangenberg HC, Viazov S, Kersting N, Neumann-Haefelin C, McKinney D,
et al. (2005) Intrahepatic CD8+ T-cell failure during chronic hepatitis C virus
infection. Hepatology 42: 828–837.
25. Zhang L, Dailey PJ, Gettie A, Blanchard J, Ho DD (2002) The liver is a major
organ for clearing simian immunodeficiency virus in rhesus monkeys. J Virol 76:
5271–5273.
26. Cao YZ, Dieterich D, Thomas PA, Huang YX, Mirabile M, et al. (1992)
Identification and quantitation of HIV-1 in the liver of patients with AIDS. Aids
6: 65–70.
27. Gea-Banacloche JC, Migueles SA, Martino L, Shupert WL, McNeil AC, et al.
(2000) Maintenance of large numbers of virus-specific CD8+ T cells in HIV-
infected progressors and long-term nonprogressors. J Immunol 165: 1082–1092.
28. Urbani S, Amadei B, Tola D, Massari M, Schivazappa S, et al. (2006) PD-1
expression in acute hepatitis C virus (HCV) infection is associated with HCV-
specific CD8 exhaustion. J Virol 80: 11398–11403.
29. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, et al. (2006) PD-1
expression on HIV-specific T cells is associated with T-cell exhaustion and
disease progression. Nature 443: 350–354.
30. Dutoit V, Ciuffreda D, Comte D, Gonvers JJ, Pantaleo G (2005) Differences in
HCV-specific T cell responses between chronic HCV infection and HIV/HCV
co-infection. Eur J Immunol 35: 3493–3504.
background is shown to become extremely low when examining combinations of functions, nearly reaching 0 events for multiple functions
simultaneously. This permits a very low threshold for detection of positive responses from multiple combinations. Consequently, for multi-parameter
analysis, the results were thresholded based on a minimum criterion of positivity, as calculated by SPICE software and presented as the 90
th
percentile of negative values for each analysis. Each pie chart generated by SPICE software, represents the hierarchy of responses to either HCV or HIV
antigen stimulation. For simplicity, responses are grouped by number of functions and matched to the colored bars, with black bars representing the
percentage of responding cells to HIV peptides and gray bars representing the percentage of responses to HCV peptide stimulation. In all pie charts,
color red represents the 5+ responding population and the colors blue, green, turquoise, and yellow representing the 4+,3 +,2 +, and 1+ populations
respectively. Color-coded arcs represent the dominant marker within each pie slice, with color blue representing TNF-a, red for CD107-a, green for
IFN-c and black for MIP-1b. Although IL-2 is included in the presentation and demonstrated by bar graphs, the software would not allow for arc colors
for more than 4 responses. As a result there is no arc representative for IL-2. Figure (c) represents the average frequency of intra-hepatic viral specific
responses within the pool of CD8
+ T-cell populations simultaneously expressing 2 functions or less, compared with those within the pool of
populations expressing more than 2 functions simultaneously; as analyzed in 3 subjects within each cohort of HCV mono and HCV/HIV co-infected
individuals. The cutoff point of simultaneous expression of more than 2 measured markers is considered to show CD8
+ T-cell poly-functionality.
Figure (d) represents PD-1 levels on HIV-1 and HCV-specific T-cells from HCV/HIV Co-infected liver (OM 385). Liver cells were stained with two pools of
HLA-A*0201-restricted pentamers (Proimmune): HCV pentamers: NS3-CINGVCWTV, NS3-KLVALGINAV and HIV pentamers: Pol-ILKEPVHGV, Gag p24-
TLNAWVKVV. PD-1 gating was based on FMO (fluorescence minus one) of the control sample.
doi:10.1371/journal.pone.0003454.g005
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